What is the expected growth forecast for the CINV market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the CINV market?

Increasing cancer incidence and chemotherapy adoption are key drivers of the CINV market.

What are the major challenges faced by the CINV market?

Limited treatment options and high treatment costs are major challenges faced by the CINV market.

Which regions are the leaders in the CINV market?

North America and Europe are the leading regions in the CINV market.

Who are the top companies in the CINV market?

Top companies include Merck, GlaxoSmithKline, and Eisai, among others.

What are the future opportunities in the CINV market?

Emerging markets and novel therapies offer future opportunities in the CINV market.

How is technology impacting the CINV market?

Digital health technologies are improving patient outcomes and enhancing the future outlook.

What is the current regulatory landscape of the CINV market?

The regulatory landscape is evolving with ongoing updates to treatment guidelines.

What is the expected future outlook of the CINV market?

The future outlook is positive with growing demand for effective treatments.

Chemotherapy-Induced Nausea and Vomiting (CINV) Size, Share & Forecast Analysis 2025–2033

Chemotherapy-Induced Nausea and Vomiting (CINV) by Application (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers), by Types (CINV, PONV), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $8.1 million

CAGR: 7.3%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $8.1 million

CAGR: 7.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview

The Chemotherapy-Induced Nausea and Vomiting (CINV) market refers to the industry focused on developing and marketing treatments for nausea and vomiting caused by chemotherapy. The Chemotherapy-Induced Nausea and Vomiting (CINV) market size is estimated to be around $2.3 billion as of 2025, with a growth outlook that is expected to drive the market forward. The market forecast suggests a compound annual growth rate (CAGR) of 7.5% from 2026 to 2033, leading to an industry expansion into new and emerging markets. The scope of the CINV market encompasses various treatments and therapies, including pharmacological interventions, alternative therapies, and complementary therapies.

Loading chart…

The growth of the CINV market is driven by several key forces, including technology shifts towards more effective and targeted therapies, regulations that support the development of new treatments, and consumer behavior that demands more personalized and convenient care. The largest region in the CINV market is North America, while the fastest-growing region is Asia-Pacific. The competitive intensity of the market is expected to increase, driven by the entry of new players and the expansion of existing ones. Overall, the CINV market is poised for significant growth and expansion, driven by a combination of macro drivers, technological advancements, and changing consumer needs.

Report Overview

Report Attribute	Details
Market size value in 2025	8.10 million
Revenue forecast in 2033	14.23 million
Growth rate	CAGR of 7.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck; Eisai; ProStrakan; Helsinn Holding; Mundipharma; Qilu Pharma; Teva; Novartis; Heron Therapeutics; Roche; Mylan; Tesaro
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Chemotherapy-Induced Nausea and Vomiting (CINV) market is witnessing significant growth due to various factors. The following sections outline the key dynamics influencing the market.

Growth Drivers2 items

Increasing cancer incidence rates and the subsequent rise in chemotherapy treatments are driving the demand for effective CINV management solutions, leading to a substantial growth forecast for the CINV market size.

Advancements in pharmacological interventions, such as the development of novel 5-HT3 antagonists and NK1 receptor antagonists, are expanding the treatment options available for CINV patients, further fueling market growth.

Restraints2 items

High treatment costs and limited reimbursement options for CINV therapies are hindering market growth, particularly in developing economies where healthcare resources are constrained.

The complexity of CINV pathophysiology and the lack of a single, universally effective treatment approach are restricting the development of new therapies and limiting the overall growth of the CINV market.

Opportunities2 items

The growing adoption of biosimilars and generic versions of established CINV therapies is expected to increase patient access to affordable treatment options, presenting opportunities for market expansion and increased CINV market size.

Emerging technologies, such as digital health platforms and wearable devices, are creating new avenues for CINV management, including remote patient monitoring and personalized treatment planning, which can improve patient outcomes and drive growth forecast.

Challenges2 items

The evolving regulatory landscape, including changing guidelines and standards for CINV treatment, poses a challenge for pharmaceutical companies and healthcare providers seeking to navigate the complexities of the CINV market.

The need for improved patient education and awareness about CINV management options and the importance of adherence to prescribed treatment regimens remains a significant challenge in optimizing patient outcomes and achieving the full potential of the CINV market size.

Market Segmentation

Loading chart…

The Application segment of the Chemotherapy-Induced Nausea and Vomiting (CINV) market is a critical component of the overall market taxonomy. This segment includes the various areas where CINV treatments are applied, such as acute CINV and delayed CINV. Understanding the application segment is essential for determining the Chemotherapy-Induced Nausea and Vomiting (CINV) segmentation and identifying potential growth opportunities.

The Types segment of the CINV market is further divided into subtypes, including [object Object] and [object Object], which represent different categories of CINV treatments. Analyzing these subtypes is crucial for understanding the market dynamics and identifying trends in the CINV market. By examining the types segment, researchers can gain insights into the market taxonomy and develop strategies to address the unique challenges of each subtype.

Chemotherapy-Induced Nausea and Vomiting (CINV) Segmentation Breakdown7 items

Application

Hospitals

Ambulatory Surgical Centers

Diagnostic Centers

Types

CINV

PONV

Regional Insights

Loading chart…

The Chemotherapy-Induced Nausea and Vomiting (CINV) market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of CINV treatments, investments in healthcare infrastructure, and a growing ecosystem maturity. Key drivers for North America include a high adoption rate of CINV medications, favorable policies, and a well-established infrastructure.

In Europe, key drivers include a large demographics of cancer patients, significant investments in research and development, and a strong ecosystem maturity. Asia Pacific's growth is driven by a rapidly increasing demographics of cancer patients, improving infrastructure, and rising adoption of CINV treatments. Latin America and Middle East & Africa are expected to experience steady growth, with key drivers including increasing awareness of CINV, growing investments in healthcare, and a developing ecosystem maturity.

The regional forecast indicates that the CINV market will continue to grow, with each region presenting unique opportunities and challenges. Understanding these regional dynamics is crucial for stakeholders to develop effective strategies and capitalize on the growing demand for CINV treatments. As the global CINV market continues to evolve, it is essential to monitor regional trends and market growth to stay ahead of the competition.

Competitive Landscape

The Chemotherapy-Induced Nausea and Vomiting (CINV) competitive landscape is moderately consolidated, with a mix of global players and local companies driving the market. Key competitive levers include pricing, distribution, product innovation, certifications, and regulatory approvals. The market is characterized by high competition, with companies focusing on differentiation through product portfolios and service models. The CINV competitive landscape is influenced by factors such as market access, reimbursement policies, and patient demographics.

Companies in the CINV market employ various strategies to gain a competitive edge, including mergers and acquisitions, partnerships, product launches, expansion, research and development, and localization. Competitive differentiation is achieved through technology, service models, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. Key players in the market include:

Merck: regional expansion

Eisai: innovation pipeline

ProStrakan: premium pricing

Helsinn Holding: local manufacturing

Mundipharma: OEM tie-ups

Qilu Pharma: vertical integration

Key Chemotherapy-Induced Nausea and Vomiting (CINV) Companies12 items

Merck

Eisai

ProStrakan

Helsinn Holding

Mundipharma

Qilu Pharma

Teva

Novartis

Heron Therapeutics

Roche

Mylan

Tesaro

Market Ecosystem

The Chemotherapy-Induced Nausea and Vomiting (CINV) ecosystem encompasses a complex network of stakeholders, spanning upstream, midstream, and downstream segments. This ecosystem is characterized by the interplay of technology providers, suppliers, integrators, channels, and end users, all of which contribute to the creation and capture of value. The CINV ecosystem is shaped by the interactions among these participants, influencing how value is created, delivered, and captured.

Raw material suppliers — provide active pharmaceutical ingredients

OEMs/manufacturers — produce CINV treatments

Technology providers — develop formulations and delivery systems

Distributors/channel partners — facilitate treatment access

Service providers/after-sales — offer patient support services

End users/buyers — receive CINV treatments

Regulators/standards bodies — oversee safety and efficacy

In the CINV ecosystem, control points are primarily held by regulators and manufacturers, influencing adoption through approvals and product development. Dependency risks arise from input constraints, such as active pharmaceutical ingredient availability, and standards, like those set by regulatory bodies. Switching costs and partnerships also play a role, with manufacturers often forming alliances to develop new treatments. Furthermore, the CINV ecosystem can differ by region due to varying regulatory requirements and healthcare infrastructure, affecting how value flows through the ecosystem and where bottlenecks occur, highlighting the need for a thorough value chain analysis.

Recent Industry Insights

The Chemotherapy-Induced Nausea and Vomiting (CINV) industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as the collaboration between pharmaceutical companies to develop novel CINV treatments, have been instrumental in driving growth. Notable mergers and acquisitions have also taken place, enabling companies to expand their product portfolios and strengthen their market presence. Furthermore, several product launches have been observed, including new formulations and delivery systems designed to improve patient outcomes.

In addition to these developments, regulatory changes have played a crucial role in shaping the CINV landscape. There has been a shift in consumer preferences towards more effective and convenient treatments, driving innovation in the industry. Funding rounds and expansions have also been announced, providing companies with the necessary resources to advance their research and development endeavors. These developments are expected to continue influencing Chemotherapy-Induced Nausea and Vomiting (CINV) industry trends in the foreseeable future.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Chemotherapy-Induced Nausea and Vomiting (CINV) market outlook. The market attractiveness is moderate, driven by the increasing incidence of cancer and the need for effective CINV treatments. Competitive intensity is high, with several key players vying for market share. The long-term outlook is promising, with the global CINV market expected to grow significantly over the forecast period.

The innovation landscape is evolving, with a focus on novel therapies and combination treatments. Demand-supply balance is a key concern, with some regions experiencing shortages of certain CINV medications. Key risk factors include the development of resistance to existing treatments and the high cost of newer therapies. Overall, the CINV market outlook is complex, with opportunities for growth and challenges to be addressed.

11 items

1. Executive Summary

2. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Ambulatory Surgical Centers

6.1.3. Diagnostic Centers

6.2. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. CINV

6.2.2. PONV

6.3. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Competition by Key Manufacturers

8.1. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Chemotherapy-Induced Nausea and Vomiting (CINV): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Merck

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Eisai

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. ProStrakan

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Helsinn Holding

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Mundipharma

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Qilu Pharma

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Teva

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Novartis

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Heron Therapeutics

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Roche

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Mylan

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Tesaro

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market

Figure 4: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market: Drivers

Figure 5: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market: Challenges

Figure 6: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market: Trends

Figure 7: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market: Opportunity

Figure 8: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market: Restraint

Figure 9: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Value (USD Million) By Region

Figure 15: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Value (USD Million) By Region

Figure 23: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Value (USD Million) By Region

Table 10: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Merck Basic Information And Sales Area

Table 31: Merck. Products Portfolio

Table 32: Eisai Basic Information And Sales Area

Table 33: Eisai. Products Portfolio

Table 34: ProStrakan Basic Information And Sales Area

Table 35: ProStrakan. Products Portfolio

Table 36: Helsinn Holding Basic Information And Sales Area

Table 37: Helsinn Holding. Products Portfolio

Table 38: Mundipharma Basic Information And Sales Area

Table 39: Mundipharma. Products Portfolio

Table 40: Qilu Pharma Basic Information And Sales Area

Table 41: Qilu Pharma. Products Portfolio

Table 42: Teva Basic Information And Sales Area

Table 43: Teva. Products Portfolio

Table 44: Novartis Basic Information And Sales Area

Table 45: Novartis. Products Portfolio

Table 46: Heron Therapeutics Basic Information And Sales Area

Table 47: Heron Therapeutics. Products Portfolio

Table 48: Roche Basic Information And Sales Area

Table 49: Roche. Products Portfolio

Table 50: Mylan Basic Information And Sales Area

Table 51: Mylan. Products Portfolio

Table 52: Tesaro Basic Information And Sales Area

Table 53: Tesaro. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Value (USD Million) By Region

Table 59: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	8.10 million
Revenue forecast in 2033	14.23 million
Growth rate	CAGR of 7.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck; Eisai; ProStrakan; Helsinn Holding; Mundipharma; Qilu Pharma; Teva; Novartis; Heron Therapeutics; Roche; Mylan; Tesaro
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Chemotherapy-Induced Nausea and Vomiting (CINV) market is witnessing significant growth due to various factors. The following sections outline the key dynamics influencing the market.

Growth Drivers2 items

Restraints2 items

High treatment costs and limited reimbursement options for CINV therapies are hindering market growth, particularly in developing economies where healthcare resources are constrained.

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Chemotherapy-Induced Nausea and Vomiting (CINV) Segmentation Breakdown7 items

Application

Hospitals

Ambulatory Surgical Centers

Diagnostic Centers

Types

CINV

PONV

Regional Insights

Loading chart…

Competitive Landscape

Merck: regional expansion

Eisai: innovation pipeline

ProStrakan: premium pricing

Helsinn Holding: local manufacturing

Mundipharma: OEM tie-ups

Qilu Pharma: vertical integration

Key Chemotherapy-Induced Nausea and Vomiting (CINV) Companies12 items

Merck

Eisai

ProStrakan

Helsinn Holding

Mundipharma

Qilu Pharma

Teva

Novartis

Heron Therapeutics

Roche

Mylan

Tesaro

Market Ecosystem

Raw material suppliers — provide active pharmaceutical ingredients

OEMs/manufacturers — produce CINV treatments

Technology providers — develop formulations and delivery systems

Distributors/channel partners — facilitate treatment access

Service providers/after-sales — offer patient support services

End users/buyers — receive CINV treatments

Regulators/standards bodies — oversee safety and efficacy

Recent Industry Insights

Analyst Overview

Table of Contents